A supplemental marketing application has been submitted to the FDA by Ocular Therapeutix for the use of Dextenza, or dexamethasone ophthalmic insert, in patients with post-ophthalmic surgery ocular inflammation. The drug was approved to treat ocular pain after ophthalmic surgery.
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.